Fintel reports that Fmr has filed a 13G/A form with the SEC disclosing ownership of 12.38MM shares of Rubius Therapeutics Inc (RUBY). This represents 13.694% of the company.
In their previous filing dated February 9, 2022 they reported 13.48MM shares and 15.00% of the company, a decrease in shares of 8.19% and a decrease in total ownership of 1.30% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 343.48% Upside
As of February 8, 2023, the average one-year price target for Rubius Therapeutics is $1.02. The forecasts range from a low of $1.01 to a high of $1.05. The average price target represents an increase of 343.48% from its latest reported closing price of $0.23.
The projected annual revenue for Rubius Therapeutics is $0MM. The projected annual EPS is -$0.66.
What is the Fund Sentiment?
There are 105 funds or institutions reporting positions in Rubius Therapeutics. This is a decrease of 92 owner(s) or 46.70% in the last quarter. Average portfolio weight of all funds dedicated to RUBY is 0.01%, a decrease of 42.92%. Total shares owned by institutions decreased in the last three months by 14.32% to 71,873K shares. The put/call ratio of RUBY is 0.02, indicating a bullish outlook.
What are large shareholders doing?
Flagship Pioneering holds 38,507K shares representing 42.61% ownership of the company. No change in the last quarter.
Baillie Gifford & holds 4,869K shares representing 5.39% ownership of the company. In it's prior filing, the firm reported owning 4,854K shares, representing an increase of 0.32%. The firm decreased its portfolio allocation in RUBY by 59.76% over the last quarter.
FDGRX - Fidelity Growth Company Fund holds 4,389K shares representing 4.86% ownership of the company. In it's prior filing, the firm reported owning 4,540K shares, representing a decrease of 3.44%. The firm decreased its portfolio allocation in RUBY by 68.69% over the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 2,254K shares representing 2.49% ownership of the company. In it's prior filing, the firm reported owning 3,167K shares, representing a decrease of 40.50%. The firm decreased its portfolio allocation in RUBY by 86.48% over the last quarter.
Artal Group holds 2,043K shares representing 2.26% ownership of the company. In it's prior filing, the firm reported owning 3,702K shares, representing a decrease of 81.21%. The firm decreased its portfolio allocation in RUBY by 77.52% over the last quarter.
Rubius Therapeutics Background Information
(This description is provided by the company.)
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
